---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-25-001734"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:14:36.711950+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CFO Andy Sassine to depart Dec 31, 2025; Controller Joe Roberts named interim CFO

## Summary
- CFO Andy Sassine and Arcturus mutually agreed to end employment effective Dec 31, 2025; he also resigned from the Board.
- Sassine receives severance: 12 months base salary ($572,000), bonus tied to CEO's 2025 bonus, 18 months COBRA, and full acceleration of 134,689 unvested stock options with 24-month exercise period.
- Joe Roberts, company Controller since March 2024, appointed interim principal financial and accounting officer; base salary $219,580, 20% target bonus.
- Board size reduced from nine to eight members effective immediately upon Sassine's resignation.
- Separation Agreement includes non-disparagement, standard release, and revocation period; severance contingent on release.

## SEC filing metadata
- accession: 0001193805-25-001734
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380525001734/0001193805-25-001734-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380525001734/e665044_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-25-001734
- JSON: https://secwatch.observer/filing/0001193805-25-001734.json
- Plain text: https://secwatch.observer/filing/0001193805-25-001734.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.